Immusoft Corporation: Comprehensive Company Profile
Executive Summary
Immusoft Corporation is an American biotechnology company focused on cell therapy and genetic medicine. Headquartered in Seattle, Washington, Immusoft is pioneering a proprietary cell therapy modality that reprograms human B cells—a specialized class of immune system white blood cells—to act as durable, in vivo "biofactories" capable of continuously producing therapeutic proteins inside a patient's body.
The company’s proprietary platform, termed Immune System Programming (ISP™), bridges genetic engineering and cellular medicine. By modifying a patient’s own B cells and coaxing them to differentiate into long-lived plasma cells, Immusoft enables sustained, steady-state production of therapeutic enzymes, antibodies, structural proteins, and signaling molecules. This approach aims to replace or enhance traditional approaches such as enzyme replacement therapy (ERT), viral gene therapies (AAV), and hematopoietic stem cell (HSC) therapies.
Continue…
Core Technology Platform: Immune System Programming (ISP™)
Biological Rationale
B cells are naturally designed to produce and secrete massive amounts of antibody proteins upon activation. When fully differentiated into plasma cells, a single cell can synthesize and secrete thousands of protein molecules per second. Immusoft leverages this cellular cellular machinery to express therapeutic proteins rather than native antibodies.
Unlike hematopoietic stem cell therapies, engineered B cells do not require myeloablative chemotherapy conditioning prior to administration. Furthermore, because the cells are autologous (harvested directly from the patient), they do not trigger graft-versus-host disease (GvHD) or immune rejection.
Step-by-Step ISP™ Process Flow
- Apheresis & Cell Collection: Blood is drawn from the patient to collect peripheral blood B cells through standard apheresis procedures.
- Selection and Purification: Target B cell subpopulations are isolated and purified from the collected cellular mixture.
- Genetic Programming: Using non-viral gene transfer methods (such as transposon-based integration systems), gene sequences encoding the desired therapeutic protein are inserted into the B cells' genome.
- Expansion and Differentiation: Using proprietary cell culture signaling protocols, the engineered B cells are expanded in vitro and induced to differentiate into plasma cells (the protein-secreting biofactory state).
- Autologous Reinfusion: The programmed plasma cells are infused back into the patient's bloodstream.
- In Vivo Protein Delivery: The infused cells migrate to bone marrow and tissues, taking up residence to deliver long-term, sustained levels of the encoded therapeutic protein.
Therapeutic Products and Pipeline
Immusoft's clinical and preclinical research targets a mix of rare genetic lysosomal storage diseases and broader, high-prevalence therapeutic areas.
1. ISP-001 (Lead Clinical Candidate)
- Target Disease: Mucopolysaccharidosis Type I (MPS I)
- Development Stage: Phase 1/2a Clinical Trial
- Mechanism of Action: MPS I is a rare, life-threatening genetic disorder caused by a deficiency in the lysosomal enzyme alpha-L-iduronidase (IDUA). Lacking functional IDUA, patients suffer toxic intracellular accumulations of glycosaminoglycans (GAGs), leading to progressive multiorgan damage, skeletal deformities, loss of mobility, and neurological impairment. ISP-001 uses the patient's own B cells programmed to continuously express and secrete functional human IDUA enzyme into circulation.
- Clinical Significance: ISP-001 represents the world's first engineered B cell therapy evaluated in human clinical trials.
2. Preclinical Pipeline Expansion
- Lysosomal Storage Diseases (LSDs): Following proof-of-concept in MPS I, Immusoft is adapting the ISP™ platform to engineer B cells for other enzyme-deficient metabolic disorders.
- Rare Genetic Diseases: Application of ISP™ to continuously express missing structural proteins or metabolic factors.
- High-Prevalence Indications: Beyond rare diseases, Immusoft is applying ISP™ to express complex biologics, such as bispecific antibodies and long-acting therapeutics for larger patient populations in oncology, immunology, and cardiovascular disorders.
Competitive Advantages & Differentiation
| Feature / Attribute | Standard Protein/ERT Therapy | AAV Viral Gene Therapy | Stem Cell (HSC) Gene Therapy | Immusoft ISP™ B Cell Therapy |
| :--- | :--- | :--- | :--- | :--- |
| Delivery Profile | Intermittent peaks and troughs ("sawtooth") | Single-dose viral delivery | Multi-step reconstitution | Continuous, steady-state secretion |
| Redosing Ability | Repeated weekly/bi-weekly infusions required | Generally non-repeatable due to neutralising antibodies | Limited / restricted by conditioning toxicity | Re-dosable without viral immune reactions |
| Conditioning Regimen | None required | None required | Requires toxic myeloablative chemotherapy | No chemotherapy conditioning required |
| Delivery Vector | Recombinant protein infusion | Adeno-associated virus (AAV) vector | Viral modification of CD34+ stem cells | Non-viral gene delivery to autologous B cells |
| Hospitalization | Frequent outpatient infusion visits | Minimal hospitalization | Extensive hospital stay for bone marrow recovery | Outpatient infusion capability |
Key Leadership Team
- Sean Ainsworth (Chief Executive Officer & Chairman): Entrepreneur with two decades of biopharmaceutical executive leadership. Previously founded RetroSense Therapeutics, a gene therapy company that advanced to human clinical trials before being acquired by Allergan.
- Robert Sikorski, M.D., Ph.D. (Chief Medical Officer): Former CMO at FivePrime Therapeutics (acquired by Amgen) with extensive background leading early-to-late stage clinical biologics pipelines at MedImmune and AstraZeneca.
- Robert Hayes, Ph.D. (Chief Scientific Officer): Biologics research executive with expertise in novel antibody platforms, cell therapies, and genetic manipulation systems. Former roles include leadership positions at Xencor and other biotech ventures.
Corporate Summary & Domain Details
- Entity Name: Immusoft Corporation
- Official Website: https://www.immusoft.com/
- Headquarters: Seattle, Washington, USA
- Primary Industry: Biotechnology / Cell & Gene Therapy
- Core Product Offering: ISP™ platform, ISP-001 cell therapy, custom B cell genetic modification services and pipeline assets.
